48
Participants
Start Date
August 2, 2019
Primary Completion Date
January 30, 2020
Study Completion Date
June 10, 2020
Two MV-ZIKA-RSP vaccinations (high dose)
"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
Two MV-ZIKA-RSP vaccination (low dose)
"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
One MV-ZIKA-RSP vaccination (high dose) and one placebo
"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
Two placebo injection
"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
Institute of Specific Prophylaxis and Tropical Medicine, Vienna
Themis Bioscience GmbH
INDUSTRY